Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high...

Descripción completa

Detalles Bibliográficos
Autores principales: Haglund, C., Roberts, P. J., Kuusela, P., Scheinin, T. M., Mäkelä, O., Jalanko, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001324/
https://www.ncbi.nlm.nih.gov/pubmed/3456787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001324/
https://www.ncbi.nlm.nih.gov/pubmed/3456787

Ejemplares similares